Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 4/20 | 0.69 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762462 | 1.00 | KCNA5 (0.69) | KCNA5SCN5ASIGMAR1SLC18A2HRH3 | |
| SCHEMBL12204055 | 1.00 | KCNA5 (0.69) | KCNA5SCN5ASIGMAR1SLC18A2HRH3 | |
| SCHEMBL1762344 | 1.00 | KCNA5 (0.69) | KCNA5SCN5ASIGMAR1SLC18A2HRH3 | |
| SCHEMBL6807137 | 0.82 | KCNA5 (1.00) | KCNA5SCN5ASIGMAR1SLC18A2KDM4E | |
| SCHEMBL2624914 | 0.82 | KCNA5 (1.00) | KCNA5SCN5ASIGMAR1SLC18A2KDM4E | |
| SCHEMBL12391697 | 0.82 | KCNA5 (1.00) | KCNA5SCN5ASIGMAR1SLC18A2KDM4E | |
| SCHEMBL12203898 | 0.81 | KCNA5 (0.82) | KCNA5SCN5ASIGMAR1SLC18A2HRH3 | |
| SCHEMBL2625053 | 0.81 | KCNA5 (0.82) | KCNA5SCN5ASIGMAR1SLC18A2HRH3 | |
| SCHEMBL8194037 | 0.81 | KCNA5 (0.47) | KCNA5SCN5ASIGMAR1ALDH1A1TSHR | |
| SCHEMBL6445899 | 0.80 | KCNA5 (0.95) | KCNA5SCN5ASIGMAR1SLC18A2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-8207219-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2012-06-26 | — | — | US | disclosed |
| US-8207219-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2012-06-26 | — | — | US | disclosed |
| US-8188140-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. | 2012-05-29 | — | — | US | disclosed |
| US-8188140-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. | 2012-05-29 | — | — | US | disclosed |
| US-20080070911-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2008-03-20 | — | — | US | disclosed |
| US-20080070911-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2008-03-20 | — | — | US | disclosed |
| US-7345086-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2008-03-18 | — | — | US | disclosed |
| US-7345086-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2008-03-18 | — | — | US | disclosed |
| US-20080004333-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004333-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-7259184-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2007-08-21 | — | — | US | disclosed |
| US-7259184-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2007-08-21 | — | — | US | disclosed |
| US-20070190156-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2007-08-16 | — | — | US | disclosed |
| US-20070004718-A1 | Ion channel modulating compounds and uses thereof | CARDIOME PHAMA CORP. (CA) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885SIGMAR1 1563/4885 |
| US-20080004333-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885SIGMAR1 1563/4885 |
| US-20070004718-A1 | Ion channel modulating compounds and uses thereof | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885SIGMAR1 1563/4885 |
| US-20080070911-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885SIGMAR1 1563/4885 |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885SIGMAR1 1563/4885 |
| US-20070190156-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885SIGMAR1 1563/4885 |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885SIGMAR1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.